Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.
COVID-19
Nrf2 activators
curcumin
macrolide
sulforaphane
viral pneumonia
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
04
2020
accepted:
26
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
The outbreak of coronavirus disease 2019 (COVID-19) pandemic has already caused a huge burden to the global healthcare system, with the death toll reached tens of thousands. Although some antiviral agents were identified and used to inhibit viral replication, the management of cytokine storm is also a critical issue. In this article, we reviewed the literature on drug candidates for severe acute respiratory syndrome (SARS-CoV-1) and provided a brief overview of a class of drugs that exert antiviral and anti-inflammatory effects. These molecules mitigated inflammatory cytokine cascades induced by viral infections via Nrf2 activating capacity and might have additional anti-fibrotic and anti-remodeling properties. Besides, their effects on the regulation of scavenger receptors expression by macrophages may offer some benefits to the pulmonary antibacterial defense system after viral infection. The potential roles of these agents assessed on the basis of the pathophysiology of viral pneumonia and acute respiratory distress syndrome were also discussed. Further research is needed to ascertain whether Nrf2 activators are useful in the management of viral pneumonia.
Identifiants
pubmed: 32606823
doi: 10.2147/IDR.S256773
pii: 256773
pmc: PMC7295331
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1735-1741Informations de copyright
© 2020 Lin and Yao.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work. This work is not funded by research grants.
Références
Clin Toxicol (Phila). 2018 May;56(5):384-385
pubmed: 28994311
Cancer Chemother Pharmacol. 2019 Feb;83(2):265-275
pubmed: 30430227
Int Immunopharmacol. 2018 Aug;61:1-7
pubmed: 29778842
Int J Antimicrob Agents. 2020 Mar 20;:105949
pubmed: 32205204
Oxid Med Cell Longev. 2019 Jul 14;2019:9372182
pubmed: 31396308
PLoS One. 2016 Jan 28;11(1):e0147742
pubmed: 26820305
Int Immunopharmacol. 2018 Jan;54:177-187
pubmed: 29153953
PLoS One. 2016 Nov 10;11(11):e0163716
pubmed: 27832073
Clin Exp Pharmacol Physiol. 2018 Jan;45(1):84-93
pubmed: 28853207
J Surg Res. 2012 Jul;176(1):e31-9
pubmed: 22520056
J Infect. 2020 Apr;80(4):394-400
pubmed: 32109443
PLoS One. 2013 May 01;8(5):e62482
pubmed: 23658730
Int J Mol Med. 2016 Jan;37(1):182-8
pubmed: 26531002
Int Immunopharmacol. 2015 Mar;25(1):55-64
pubmed: 25614226
Brain Res. 2009 Aug 25;1286:174-84
pubmed: 19523933
Antiviral Res. 2019 Nov;171:104590
pubmed: 31421166
Ann Transl Med. 2018 Jan;6(2):24
pubmed: 29430441
Chin Med J (Engl). 2018 Jul 20;131(14):1686-1693
pubmed: 29998888
Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L138-L153
pubmed: 28408365
Respirology. 2008 Mar;13(2):215-20
pubmed: 18339018
Mediators Inflamm. 2012;2012:649570
pubmed: 22719178
Dermatol Ther. 2020 Apr 20;:e13437
pubmed: 32314492
J Investig Med. 2010 Jun;58(5):730-6
pubmed: 20216230
J Med Chem. 2007 Aug 23;50(17):4087-95
pubmed: 17663539
Vaccine. 2001 Jun 14;19(27):3744-51
pubmed: 11395209
Vaccine. 2009 Apr 21;27(18):2418-25
pubmed: 19368783
Inflammopharmacology. 2019 Aug;27(4):731-748
pubmed: 30470954
Int J Pharm. 2018 Nov 15;551(1-2):212-222
pubmed: 30227240
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Front Microbiol. 2019 May 03;10:912
pubmed: 31130924
Am J Chin Med. 2017;45(6):1253-1271
pubmed: 28830206
PLoS One. 2013;8(2):e57285
pubmed: 23437361
Biomed Res Int. 2014;2014:186864
pubmed: 24877064
Influenza Other Respir Viruses. 2017 Sep;11(5):457-463
pubmed: 28646616
Oxid Med Cell Longev. 2019 Jan 8;2019:7090534
pubmed: 30728889
Free Radic Biol Med. 2011 Jul 15;51(2):444-53
pubmed: 21549835
J Biol Regul Homeost Agents. 2009 Apr-Jun;23(2):119-23
pubmed: 19589293
Am J Respir Crit Care Med. 2018 Sep 15;198(6):739-750
pubmed: 29547002
Front Immunol. 2018 Mar 13;9:302
pubmed: 29593707
Kidney Int. 2013 Dec;84(6):1090-5
pubmed: 23783243
J Integr Med. 2018 Nov;16(6):367-374
pubmed: 30006023
Int J Mol Sci. 2018 Dec 17;19(12):
pubmed: 30562944
Am J Respir Crit Care Med. 2009 Jan 15;179(2):138-50
pubmed: 18931336
Oxid Med Cell Longev. 2019 Oct 14;2019:2716870
pubmed: 31737167
BMC Pharmacol Toxicol. 2017 Feb 25;18(1):15
pubmed: 28235416
Comp Immunol Microbiol Infect Dis. 2018 Feb;56:6-13
pubmed: 29406285
Exp Ther Med. 2018 Jun;15(6):4911-4915
pubmed: 29805514
Sci Transl Med. 2011 Apr 13;3(78):78ra32
pubmed: 21490276